Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,008 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-190 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.3
Industry P/E
--
EV/EBITDA
-3.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-4
Face value
--
Shares outstanding
47,860,400
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Forma Therapeutics Holdings (FMTX)
| 40.7 | 0.4 | 125.6 | 13.4 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
|---|---|
|
Forma Therapeutics Holdings (FMTX)
| -59.3 |
|
S&P Small-Cap 600
| 25.3 |
|
BSE Sensex
| 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Forma Therapeutics Holdings (FMTX)
|
20.0 | 1,007.8 | 0.0 | -190.2 | -- | -41.7 | -- | 2.3 |
| 2.2 | 93.4 | 665.5 | -43.0 | -6.0 | -32.9 | -- | 0.5 | |
| 21.0 | 2,941.2 | 4,649.0 | -13.0 | 0.0 | -0.9 | -- | 2.0 | |
| 17.6 | 814.1 | 175.5 | -702.0 | -549.2 | -- | -- | 9.5 |
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development... include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S. Read more
Pres & CEO
Mr. Frank D. Lee
Pres & CEO
Mr. Frank D. Lee
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Forma Therapeutics Holdings Inc (FMTX) is $20.01 (NASDAQ) as of 21-Oct-2022 09:30 EDT. Forma Therapeutics Holdings Inc (FMTX) has given a return of 13.44% in the last 1 years.
Since, TTM earnings of Forma Therapeutics Holdings Inc (FMTX) is negative, P/E ratio is not available.
The P/B ratio of Forma Therapeutics Holdings Inc (FMTX) is 2.31 times as on 11-Nov-2022, a 44 discount to its peers’ median range of 4.12 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-3.86
|
1.34
|
|
2020
|
-11.40
|
1.24
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2021
|
-3.86
|
1.34
|
The 52-week high and low of Forma Therapeutics Holdings Inc (FMTX) are Rs -- and Rs -- as of 03-Apr-2026.
Forma Therapeutics Holdings Inc (FMTX) has a market capitalisation of $ 1,008 Mln as on 11-Nov-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Forma Therapeutics Holdings Inc (FMTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.